Drug Trial Radar · NCT04588311
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,500
Planned (sponsor's estimate)
Start
Nov 9, 2020
Primary completion
Dec 31, 2026
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Australian and New Zealand Intensive Care Research CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University College Dublin; Medical Research Institute of New Zealand; Medical Research Future Fund; Health Research Board, Ireland; Health Research Council, New Zealand; Irish Critical Care Clinical Trials Network; ANZICS Clinical Trials Group; Monash University
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and severe disability at six months in critically ill trauma patients. 2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting to the ICU will be recruited into the study from participating study centres in Australia, New Zealand, Europe, and Saudi Arabia.
Conditions
- Trauma
- Traumatic Injury
- Traumatic Brain Injury
- Wounds and Injuries
- Penetrating Injury
- Blunt Injury
- Major Trauma
- Multiple Trauma
Interventions
Epoetin Alfa 40000 UNT/MLDrug
Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
Sodium Chloride 0.9%Drug
Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined proportion of participants who have died or have severe disability (WHODAS 2.0 > 25)Time frame: 6-months
Locations
41 sites in 9 countries. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia · Active not recruiting
St George Hospital
Kogarah, New South Wales, Australia · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
John Hunter Hospital
New Lambton Heights, New South Wales, Australia · Recruiting
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Royal Darwin Hospital
Tiwi, Northern Territory, Australia · Not yet recruiting
Cairns Hospital
Cairns, Queensland, Australia · Withdrawn
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia · Recruiting
Gold Coast University Hospital
Southport, Queensland, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Flinders Medical Centre
Adelaide, South Australia, Australia · Not yet recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Royal Melbourne Hospital
Melbourne, Victoria, Australia · Recruiting
Royal Perth Hospital
Perth, Western Australia, Australia · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Not yet recruiting
HUB Hopital Erasme
Brussels, Belgium · Not yet recruiting
CHU-Charleroi Chimay
Charleroi, Belgium · Recruiting
Ziekenhuis Oost-Limburg
Genk, Belgium · Not yet recruiting
Ghent University Hospital
Ghent, Belgium · Not yet recruiting
CHR de la Citadelle de LIEGE
Liège, Belgium · Not yet recruiting
Helsinki University Hospital (HUS)
Helsinki, Finland · Recruiting
Kuopio University Hospital
Kuopio, Finland · Recruiting
Turku University Hospital
Turku, Finland · Recruiting
University Hospital Münster
Münster, Germany · Recruiting
Beaumont Hospital
Beaumont, Ireland · Recruiting
Cork University Hospital
Cork, Ireland · Recruiting
St Vincent's University Hospital
Dublin, Ireland · Recruiting
Auckland City Hospital
Grafton, Auckland, New Zealand · Recruiting
Christchurch Hospital
Christchurch, Christchurch, New Zealand · Recruiting
Middlemore Hospital
Auckland, Otahuhu, New Zealand · Recruiting
Waikato Hospital
Hamilton, Waikato Region, New Zealand · Recruiting
Wellington Hospital
Newtown, Wellington Region, New Zealand · Recruiting
King Abdulaziz Medical City
Riyadh, Saudi Arabia · Recruiting
University Medical Centre Ljubljana
Ljubljana, Slovenia · Recruiting
University Medical Centre Maribor
Maribor, Slovenia · Recruiting
University Hospital Bern
Bern, Switzerland · Recruiting
Lucerne Cantonal Hospital
Lucerne, Switzerland · Not yet recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.